- Trial phase
- Phase 3
- Time to market
- Likely several years away; Phase 3 trials are recruiting with primary completion estimated around 2029 for the colorectal cancer trial. Breakthrough Therapy Designation could enable accelerated FDA review if AbbVie files based on interim data, but no filing has been announced.
- Why 4/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months; the Phase 3 AndroMETa trials are still recruiting with primary completion estimated around 2029, and no regulatory filing has been announced. Temab-A is also one of many pipeline programs at a mega-cap diversified pharma, limiting its share-price impact.
The next major catalysts for Temab-A will be interim or final Phase 3 data readouts from the AndroMETa-CRC-560 (NCT07525206) and AndroMETa-Lung-713 (NCT07155187) trials, but these are likely years away (primary completion estimated around 2029 for CRC). Watch for potential accelerated filing based on the Breakthrough Therapy Designations, which could compress the timeline, but no regulatory submission has been announced yet.
Price Chart
Executive Summary
Temab-A (telisotuzumab adizutecan, ABBV-400) is AbbVie's next-generation antibody-drug conjugate targeting the c-Met protein, which is overexpressed in many solid tumors. On October 7, 2026, the FDA granted it two Breakthrough Therapy Designations for colorectal cancer (in combination with bevacizumab) and non-small cell lung cancer (as monotherapy), based on encouraging Phase 1 data. The drug is now in multiple Phase 3 trials (AndroMETa program) that are actively recruiting, with primary completion estimated around 2029. For AbbVie, a mega-cap diversified pharma with roughly $61 billion in annual revenue and a market cap near $295 billion, Temab-A is a promising but early-stage pipeline asset. No PDUFA date or pivotal readout is imminent, limiting its near-term stock-moving potential.
How It Works
Temab-A is an antibody-drug conjugate (ADC), a type of precision cancer therapy. It works like a guided missile: one part of the drug (the antibody) latches onto a protein called c-Met that is found in high amounts on the surface of many cancer cells, and the other part delivers a chemotherapy payload (a topoisomerase 1 inhibitor) directly inside those cells, killing them while largely sparing healthy tissue.
Trial Status
Temab-A is in multiple Phase 3 and Phase 2/3 trials across colorectal cancer (AndroMETa-CRC-560, NCT07525206, recruiting ~990 patients) and non-small cell lung cancer (AndroMETa-Lung-713, NCT07155187). Additional Phase 2 studies are exploring gastric, esophageal, and head and neck cancers. The Phase 1 first-in-human study (NCT05029882) has reported encouraging efficacy data in heavily pretreated patients, which supported the Breakthrough Therapy Designations.
The Two-Sided Case
Upcoming Catalysts
- Potential interim data from ongoing Phase 3 AndroMETa trials (timing uncertain, likely 2027+ given 2029 primary completion estimates)
- Possible accelerated regulatory filing based on Breakthrough Therapy Designation (no announcement yet)
- Additional data presentations at major medical conferences (ASCO, ESMO, WCLC, ESMO)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report